NCT06922305View on ClinicalTrials.gov

Relative Bioavailability Study of HR19042 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 27, 2023

Primary Completion Date

January 25, 2024

Study Completion Date

January 25, 2024

Conditions
Primary IgA Nephropathy; Autoimmune Hepatitis
Interventions
DRUG

HR19042 Capsule, Tarpeyo®, Budenofalk®

In each period under fasting conditions, subjects received oral administration of either HR19042 Capsule 16 mg, Tarpeyo® 16 mg, or Budenofalk® 15 mg.

Trial Locations (1)

610072

Sichuan Provincial People's Hospital, Chengdu

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT06922305 - Relative Bioavailability Study of HR19042 in Healthy Subjects | Biotech Hunter | Biotech Hunter